当前位置: X-MOL 学术Aging Male › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Hematologic parameters are not predictors of upgrading or treatment in a racially diverse prospective study of men with prostate cancer on active surveillance.
The Aging Male ( IF 2.6 ) Pub Date : 2020-06-05 , DOI: 10.1080/13685538.2020.1772227
T Maxwell Shelton 1 , Jacob W Greenberg 1 , Jonathan L Silberstein 1 , L Spencer Krane 1
Affiliation  

Introduction: Neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte ratios (PLR) are useful clinical biomarkers for prognosis in several malignancies. Their predictive value has been less clearly demonstrated with prostate cancer (PCa), particularly, their utility within active surveillance (AS) protocols. We aim to evaluate NLR and PLR in AS patients.

Methods: We identified 98 patients who met inclusion criteria in our cohort of 274 men diagnosed with PCa on AS. Patients were then categorized into high and low NLR and PLR groups.

Results: The 2.5 and 5-year Gleason upgrading free probability for our high NLR cohort was 73.9%(CI 56.3% to 97.0%) and 46.2%(CI 22.4% to 95.1%) compared to 76.3%(CI 65.7% to 88.7%) and 61.7%(CI 47.7% to 80.0%) in the low NLR cohort(p = .73). The 2.5 and 5-year Gleason upgrading free probability for our High PLR cohort was 73.5%(CI 57.3% to 94.2%) and 60.1(CI 41.4% to 87.4%) compared to 76.8%(CI 65.8% to 89.65) and 58.1%(CI 42.2% to 80.1%) in our low PLR group(p = .41). A multivariant analysis demonstrated these groups were not significant predictors of upgrading or treatment.

Conclusion: Despite their usefulness in many types of malignancy, NLR and PLR were not predictors of upgrading or treatment in men on AS for localized PCa in our cohort.



中文翻译:

在一项针对积极监测的前列腺癌男性的种族多样化前瞻性研究中,血液学参数不是升级或治疗的预测因素。

简介:中性粒细胞与淋巴细胞 (NLR) 和血小板与淋巴细胞比值 (PLR) 是几种恶性肿瘤预后的有用临床生物标志物。它们的预测价值在前列腺癌 (PCa) 中的表现不太清楚,特别是它们在主动监测 (AS) 方案中的效用。我们旨在评估 AS 患者的 NLR 和 PLR。

方法:我们在我们的 274 名被诊断为 AS 的 PCa 男性的队列中确定了 98 名符合纳入标准的患者。然后将患者分为高和低 NLR 和 PLR 组。

结果:我们的高 NLR 队列的 2.5 年和 5 年 Gleason 无升级概率分别为 73.9%(CI 56.3% 至 97.0%)和 46.2%(CI 22.4% 至 95.1%),而 76.3%(CI 65.7% 至 88.7%) ) 和 61.7% (CI 47.7% to 80.0%) 在低 NLR 队列中 ( p  = .73)。我们的高 PLR 队列的 2.5 年和 5 年 Gleason 免费升级概率分别为 73.5%(CI 57.3% 至 94.2%)和 60.1(CI 41.4% 至 87.4%),而 76.8%(CI 65.8% 至 89.65)和 58.1% (CI 42.2% to 80.1%) 在我们的低 PLR 组中 ( p  = .41)。多变量分析表明,这些组不是升级或治疗的重要预测因子。

结论:尽管 NLR 和 PLR 在许多类型的恶性肿瘤中有用,但在我们的队列中,NLR 和 PLR 并不是 AS 男性局部 PCa 升级或治疗的预测因子。

更新日期:2020-06-05
down
wechat
bug